Wall Street Breakfast cover image

Next stage of AI revolution arrives

Wall Street Breakfast

00:00

ScholarRock Faces FDA Complete Response Letter

Kim Kahn explains ScholarRock's FDA setback for epitogromab and implications for its SMA treatment approval path.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app